Predictive biomarkers for immunotherapy efficacy in neuroendocrine neoplasms

#4285

Introduction: The application of immunotherapy in NENs is still in its early stages. Identifying reliable predictive biomarkers of efficacy is critical for research, enabling better selection of patients who are more likely to respond to immunotherapy and improving treatment success rates.

Aim(s): To explore the feasibility of PD-L1 expression, TMB, MSI, CD8 tumour-infiltrating lymphocytes (TILs), and intratumour heterogeneity (ITH) as predictive biomarkers for the efficacy of immunotherapy in NENs.

Materials and methods: A retrospective analysis was conducted on patients who were treated at Centre for Neuroendocrine Tumors of Fudan University Shanghai Cancer Center between July 2021 and January 2024. These patients had undergone immunotherapy and had available results for PD-L1 expression, TMB, MSI, CD8 TILs and ITH.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Sun Z, Jia X, Chen J,

Keywords: immunotherapy, biomarker, neuroendocrine neoplasm,